You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

COPD Guidelines and Guidance

HTA COPD guidance for Incruse Ellipta

See the Scottish Medicines Consortium (SMC) guidance for Incruse in COPD [1]

SMC Advice

Following a full submission:

Umeclidinium (Incruse®) is accepted for use within NHS Scotland.

Indication under review: as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

Two randomised controlled, phase III studies demonstrated that after 12 and 24 weeks of treatment umeclidinium improved lung function compared with placebo in patients with moderate to severe COPD. There was also improvement in symptomatic outcomes such as dyspnoea.

Umeclidinium is an alternative to other long-acting muscarinic antagonists (LAMAs).

See the All Wales Medicines Strategy Group (AWMSG) guidance for Incruse in COPD [2]

AWMSG advice

Umeclidinium (Incruse) is recommended as an option for use within NHS Wales as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease.

National Institute for Health and Care Excellence (NICE) 2010 COPD Guidelines [3]
You can access the guideline by clicking here: NICE CG101 quick reference guide for the treatment of COPD.

NICE has yet to review Incruse.

Global Initiative for Chronic Obstructive Lung Disease (GOLD) COPD Guidelines [4]
You can access the guideline by clicking here: www.goldcopd.org

Reference:

  1. Scottish Medicines Consortium. Umeclidinium, 55 micrograms, powder for inhalation (Incruse®). Glasgow, 2014. Available from http://www.scottishmedicines.org.uk/files/advice/umeclidinium - November 2014. Date last accessed: December 2016
  2. All Wales Medicines Strategy Group. Umeclidinium (Incruse®) 55 micrograms inhalation powder. Reference No. 1352. 2015. Available from http://www.awmsg.org/awmsgonline/app/appraisalinfo/1352 - November 2014. Date last accessed: December 2016
  3. National Institute for Health and Clinical Excellence. Chronic obstructive pulmonary disease: Management of chronic obstructive pulmonary disease in adults in primary and secondary care (partial update). London: National Clinical Guidline Centre; 2010. http://www.nice.org.uk/CG101. Last accessed: December 2016 
  4. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. Available from: http://www.goldcopd.org/. Last accessed: December 2016

Incruse and Relvar are registered trademark of the GlaxoSmithKline group of companies.